Does epilepsy contribute to the clinical phenotype of C9orf72 mutation in fronto-temporal dementia?

C9orf72 mutation Epilepsy Fronto-temporal dementia Progressive primary aphasia

Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
08 2022
Historique:
received: 06 03 2022
revised: 17 05 2022
accepted: 30 05 2022
pubmed: 26 6 2022
medline: 8 7 2022
entrez: 25 6 2022
Statut: ppublish

Résumé

C9orf72 mutation is the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) worldwide. Recently, several reports of patients with FTD who carried the C9orf72 mutation and also manifested epilepsy have been published, since seizures occur in FTD at a higher rate than in the general population, the possible association between epilepsy and C9orf72 mutation remains to be clarified. In the attempt to understand whether epilepsy contributes to the phenotype of the C9orf72 mutation, we compared epilepsy occurrence in patients with FTD who carried the C9orf72 mutation and those who did not. In our sample of 84 patients with FTD, 7.1% of cases reported epilepsy, with no significant differences between subsamples of patients with FTD stratified according to the presence of the C9orf72 mutation or to family history of FTD/parkinsonism/motor neuron disease. Our findings did not support to the possibility that epilepsy represents a characteristic feature of the C9orf72 mutation, as suggested by recent case reports published in the English literature.

Identifiants

pubmed: 35752055
pii: S1525-5050(22)00232-3
doi: 10.1016/j.yebeh.2022.108783
pii:
doi:

Substances chimiques

C9orf72 Protein 0
C9orf72 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108783

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Antonella Muroni (A)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy. Electronic address: antonellamuroni79@gmail.com.

Gianluca Floris (G)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

Lorenzo Polizzi (L)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

Laura Fadda (L)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy.

Giuseppe Piga (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Giulia Primicerio (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Lorenzo Rocchi (L)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Giovanni Defazio (G)

Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH